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we, elevated serum creatinine, preoperative ECG ischemic abnormalities or signs of 
hypertrophy, positive stress test, and had a worse functional StatuS. all risk factors of 
MCC in that cohort (all p < 0.05). Using mUltipIe logistic regression analysis. Signs Of 
ischemia on the immediate PO ECG remained an independent predictor of MCC (Odds 
Ratio (O&1.6; 95% Confidence Interval (CI)=l.O-3.3, p&05). Furthermore. stratifica- 
tion by initial Revised Cardiac index showed that despite lower preoperative risk assess- 
ment (Class I-II). presence of ischemia on the immediate PO ECG identified a subgroup 
of patient with higher risk of MCC (O&4.2. 95%CI=1.4-12.6). In class III-IV patients, PO 
ischemia was also associated with higher incidence of MCC (OR=2.0, 95%Cl=l.l-3.6). 
Conclusion: Signs of ischemla on the immediate PO ECG were associated with higher 
MCC rate, even in patients stratified at low risk preoperatlvely. These results argue for 
routine performance of the ECG in the recovery room following major NC surgery. 
a:45 a.m. 
884-2 Time to Relapse of Atrial Fibrillation and Signal- 
Averaged P Wave Duration 
uDlxen, Jan Pamer, Vemer Rasmussen, Steen M. Pehrson, Gorm B. Jensen, The 
University Hospital of /fvidovre, Copenhagen, Denmark. 
Background: Prolonged Signal-Averaged P Wave Duration (SAPD) has been established 
as a risk marker for atrial fibrillation. We assessed the time to first symptomatic atrial 
fibrillation relapse in patients with earlier or present atrial fibrillation in relation to the 
SAPD, clinical characteristics of the patients, and the duration of the atrial fibrillation dis- 
ease. 
Methods-111 consecutive patients (71/40 men/women; median age 65 years, range 30- 
65 years) with earlier or acute atrial fibrillation were enrolled. Patients undergoing elec- 
tive cardioversion of long-lasting atrial fibrillation during the inclusion period were not 
included. The SAPD was measured at inclusion, and the follow-up time was six months 
(median 164 days; range 171-437 days). The time to first relapse of atrial fibrillation was 
regarded as endpoint treating deaths without atria1 fibrillation and patients without 
relapse during follow-up as censorings. 
Results- During follow-up 50 patients had a symptomatic attack of atrial fibrillation. Pro- 
portional hazard regression analysis showed a significant effect of moderately prolonged 
SAPD 135145 ms (hazard ratio 3.31, Cl 1.47.7.46), of severely prolonged SAPD above 
145 ms (hazard ratio 2.74, Cl 1.23-6.12), a common p value of 0.005, and of longer total 
duration of the atrial fibrillation disease than two years (hazard ratio 2.06, Cl 1.13-3.75, 
p=O.O2). We found no predictive effect of age, gender, diagnosed hypertension, the left 
atrial diameter or low ejection fraction. 
Conclusions: Risk factors for early atrial fibrillation relapse were prolonged signal-aver- 
aged P wave duration above 135 ins, and a total duration of atria1 fibrillation disease 
longer than two years. 
9:00 a.m. 
884-3 Ventricular Gradient Is an Independent Risk Factor in 
Survivors of Acute Myocardial Infarction 
y.&J& N. Batchvu, Katerina Hnatkova, Azad Ghuran, Jan Poloniecki, Peter 
Smetana, A John Camm, Marek Malik, StGeoge’s Hospifal Medical School, London, 
United Kingdom. 
Ventricular gradient (VG) reflects inhomogeneity of ventricular repolarisation. Its relation to 
prognosis in myocardiil infarction (Ml) is unknown. We examined multivariately the link 
between an optimised version of VG (TCRT, angular difference between spatial QRS and T 
vectors) and cardiac mortality in survivors of acute Ml. 
Methods: Age, left ventricular ejection fraction (EF), QRS duration on signal-averaged ECG 
(SAECG), ventricular ectopicshour, mean RR interval, heart rate variability (HRV) index, 
heari rate turbulence slope on 24.hour Halter, and TCRT (calculated from averaged XYZ 
leads of the SAECGs) were measured before discharge in 1047 Ml survivors (age 58*9 
years, 61% men). During a follow-up censored at 5 years, 124 (12%) cardiac deaths 
occurred. All parameters were dichotomised by the percentile separating 20% of pts with 
the most risk-associated values. 
Results: EFc33% (relative risk (RR) 2.9, 95%CI: 1.4-5.6, psO.003) and TCRT<-0.66 (RR 
3.4, Cl 1.6-6.4. p=O.O002) were independent predictors of 5year cardiac mortality, while 
HRV tndexl6.3U (RR 3.6, Cl 1.2-11.3. p=O.O3) and TCRTc-O.66 (RR 2.9, Cl 1.2. 
7.1 .p=O.O2) were independent predictors of 1 -year cardiac mortality.Five-year cardiac mor- 
tality in pts with both EF>33% and TCRT>-0.66 was appr. 6%, in pts with either EF<33% or 
TCRT<-0.68 it was appr.l6%. and in pts with both EF<33% and TCRTc-0.66 it was >50% 
(Figure). 
Conclusions: Decreased TCRT (‘optimised’ VG) is an independent predictor of cardiac 
death in survivors of acute MI. 
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884-4 Does Atrial Electrlcal Function in Patients With Atrial 
Flutter Recover? 
m, Hidekazu Hirao, Sou Takenaka, Yukiko Nakano, Kentaro Ueda. Kenya 
Sakai. Keiji Matsuda. Yukihiro Fukuda, Hiroki Teragawa, Togo Yamagata. Hideo 
Matsuura. Kazuaki Chayama, First Department of Internal Medicine, Hiroshima 
University School of Medicine, Hiroshima, Japan. 
Background: The P wave signal-averaged electrocardiogram (PSAE) has been clinically 
applied to detect patients with paroxysmal atrial fibrillation. However, little is known about 
patients with atria1 flutter (AFL). We analyzed PSAE of patients after successful catheter 
ablation for AFL to determine whether atrial electrical function in patients with AFL 
recover. 
Methods: The study group consisted of 10 patients undergoing ablation of chronic coun- 
terclockwise typical AFL. The flutter cycle length was 251*7ms. The patients had docu- 
mented AFL for 2lfl7months. The control group consisted of 20 patients without any 
arrhythmias. Ablation was performed by creating a linear lesion between the tricuspid 
annulus and inferior vena cava. AFL ablation end point was bidirectional isthmus block. 
PSAE was recorded 1 day, 7 days and 1 month after the ablation. We measured the fil- 
tered P wave duration (PD) and the root mean voltage (LP20, LP30) for the terminal 20 
and 30 ms of the filtered P wave. 
Results: All patients were no recurrence of AFL for 1 month after the ablation. The PD 
was significantly prolonged in patients with AFL at lday after the ablation compared with 
control group (161i17 vs. 134?llms, p=O.O003). LP20 and LP30 were lower in patients 
with AFL than those in control group (1.4fo.5 vs. 2.011.OpV; 1.9fo.2 vs. 3.0+1.6lV, 
respectively). PD was 161+17, 156f30 and 146k21ms; LP20 was 1.4m.5, 2.0x).7 and 
3.0*1 .OFV; LP30 was 1.9fl.2, 2.6i0.7 and 3.7+1.2pV at 1 day, 7 day and 1 month after 
the ablation. LP20 and LP30 were greater at 1 month than those at 1 day (p=O.O02, 
p=O.OOl) 
Conclusion: The findings of this study showed: 1) The PD was significantly prolonged in 
patients with AFL. And this prolongation was improved for 1 month after the ablation; 2) 
LP20 and LP30 were greater in 1 month after the ablation than those in 1 day. These 
findings suggest that atrial electrical dysfunction in patients with AFL recover for 1 month 
after the ablation. Catheter ablation for AFL can improve the electrical substrate of atrial 
fibrillation in patients with atrial fibrillation/flutter. PSAE may be clinical use to distinguish 
the patients with recurrence of AFL or atrial fibrillation from those without recurrence. 
930 a.m. 
884-5 Deficits in Knowledge Related to the OT Interval That 
Could Impact Patient Safety 
mM. Sana M. Al-Khatib, Judith M. Kramer, Judy Battle, Robert M. 
Califf. Duke Clinical Research Institute, Durham, North Carolina. 
Background: Several medications have recently been removed from the US drug market 
because of QT-interval (QTI) prolongation and torsade de pointes. Despite labeling 
changes and warnings to attempt to reduce inappropriate use of these agents and mini- 
mize the risk of torsade de pointes, inappropriate prescribing continued to occur. Since 
many other QTI-prolonging medications remain on the market, we conducted an evalua- 
tion of practitioner knowledge of the QTI and medications that may cause QTI- prolonga- 
tion to determine if knowledge deficits exist that could partially explain the inappropriate 
use of these agents in clinical practice. 
Methods: Practitioners were surveyed at a cardiology symposium in November 2000 and 
a meeting of cardiology investigators in February 2001. The number and percentage of 
practitioners who correctly answered questions related to the QTI were detenined. 
Results: A total of 334 respondents completed the survey [127 (36%) physicians, 149 
(45%) nurses, 30(9%) physicians in training, 16(5%) unspecified, 5(2%) study coordina- 
tors, 4 (1%) physician assistants, and 3 (0.9%) pharmacists]. Cardiology was the area of 
specialization for 271 (61%) of the respondents. Eighty-six percent of respondents stated 
that they would measure a QTI before and after starting a QT prolonging medication. 
Sixty-one percent were able to identify what the QTI represented on an EKG, but only 
36% ware able to measure a QTI Twenty percent were able to identify causes of QTI 
prolongation, and 7% were able to identify patient factors associated with increased risk 
of torsade de pointes. Less than 1% of respondents were able to correctly identify drugs 
that prolong the QTI or drug combinations that prolong the QTI. 
Conclusion: Although most cardiology practitioners said that they measured the QTI 
when starting a QTI-prolonging medication, this survey indicated marked deficiencies in 
their ability to correctly measure the QTI and to identify patient factors and medications 
associated with QTI prolongation. This study demonstrates the need to improve practitio- 
ners knowledge on this important patient safety issue 
9:45 a.m. 
884-6 Prolonged PR Interval Is Associated With increased 
Risk of Atrial Fibrillation: The Framingham Heart Study 
Vasan Marlin G. Larson, Daniel Levy, Eric P. Leip, Ralph B. 1 
D’Agostino, Sr., Philip A. Wolf, William B. Kannel, Emelia J. Benjamin, NHLBl’s 
Framingham Heart Sfudv, Framingham, Massachusetts, Boston University School Of 
Medicine, Boston, Massachuseffs. 
Background: P wave prolongation on the ECG is associated tith increased risk of atrial 
fibrillation (AF). The PR interval is an easily measured marker of atrial and atrioventricu- 
lar conduction. We hypothesized that prolonged PR interval may be associated with 
increased risk of AF. 
Methods: We examined the association ot PR interval, measured with digital calipers on 
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a resting ECG, in 7304 Framingham Heart Study subjects (3965 women; mean age 46 
years) who attended a routine examination and had no prior AF. Sex-specific Cox propor- 
tional hazards regression models were used to examine Me association of PR interval 
with risk of AF after adjusting for age, BMI, smoking, hypertension, diabetes, valve dis- 
ease, MI or CHF [time-dependent covariate]), presence of atrial premature beats and lef! 
ventricular hyperfrophy. 
Results: On follow up (mean 21 years), 624 subjects (290 women) developed AF. In 
multivariable models adjusting for established risk factors, a nonlinear relation was noted 
between PR intewal and risk of AF. Comparing subjects with short (co.12 set) and pro- 
longed PR intervals (>0.20 set) with those with a normal PR (0.12-0.20). a prolonged PR 
interval was associated with increased risk of AF in both sexes (Table). 
Conclusions: Contrary to previous reports, a prolonged PR interval is not a benign con- 
dition. It is associated with increased risk of AF, perhaps because it identifies subjects 
with nonuniform or delayed atrial conduction. 
PR Interval and Risk 01 lncldent AF 
category Men Women 
No. AF/ No. at Risk HR (95% Cl)’ No. AF/ No. at Risk HR (95% Cl) 
Normal PR 
Short PR 
Long PR 
313/3176 1 .O (Referent) 
6/60 1.9 (0.6-4.3) 
15/61 1.7 (1 .o-2.9) 
27613770 1 .O (Referent) 
6/l 76 1.2 (052.6) 
6/29 3.6 (1.7-7.6) 
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885-l Pulmonary Vein Isolation for Treatment of Atrial 
Fibrillation: Impact of Age on Success and 
Complications 
vDresina. Nassir F. Marrouche, David 0. Martin, Christopher Cole, Ahmad Abdul- 
Karim, Robert Bchweikert, Eduardo Saad, Ktzystof Balaban, Patrick Tchou, Walid Saliba, 
Andrea Natale, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Isolation of the pulmonary veins (PV) guided by the circular mapping is 
used for treatment of atrial fibrillation (AF). We compare success rates and long term fol- 
low-up in relation to patients age. Methods and Results: One hundred and sixty-six 
patients (135 men; mean age 53+/-H years) presented for focal mapping and ablation of 
paroxysmal (93 patients) persistent (25 patients) and permanent (46 patients) symptom- 
atic AF. All patients failed 3 +/- 0.9 antiarrhythmic drugs (AAD). Success rate and long- 
term follow-up ware assessed in three different age groups. 570 PVs were mapped and 
isolated using the circular mapping technique. The relative risk of recurrence was 2.5 fold 
higher in patients >= 50 years. 
Conclusion: Isolation of the PVs is an effective cure for atrial fibrillation. From our prelim- 
inary data younger patients (age <50 years) seems to benefit the most from PVs isolation 
for the treatment of AF. Moreover, in our series the younger patients experienced no 
major complications. Pulmonary veins isolation could be considered as first line therapy 
in this group of patients. 
Number of patients 
Age-z50 
Group 1 
57 (46/11) 
Age 50-60 
Group 2 
57(47/10) 
Age>60 
Group 3 
52(42/10) 
(M/F) 
Mean age (years) 
Duration (years) 
Left atrial size (cm) 
Follow-up 
Recurrence 
Controlled on AAD 
Tamponade 
Stroke 
41+/-a 
5+/-3 
4+/-0.3 
5.6+/-3.4 
7% (2/57) 
3.5% (2/57) 
0 
0 
55+/-2 
5+/-4 
4.2+/-0.4 
6+/-3.5 
23%(13/57) 
5% (3/57) 
0 
0 
65+/-4 
6+/-3 
4.3+/-0.5 
5.6+/-3.1 
17%(9/52) 
6%(4/57) 
4%(2) 
4% (2) 
8:45 a.m. 
885-2 Clinical Slgnlflcance of Early Recurrence of Atrial 
Fibrillation After Pulmonary lsolatlon in Patients With 
Paroxysmal Atrlal Flbrlllatlon 
H&a&r&, Hiroshi Tada, Mehmet Ozaydin, Amen Chugh, Sohail Hassan, Christoph 
Scharf, Radmira Greenstein, Frank Pelosi, Jr., Bradley P. Knight, S. Adam Strickberger, 
Fred Morady, Univmity of Michigan, Ann Arbor, Michigan. 
Background: Radiofrequency (RF) catheter ablation of the pulmonary vein (PV) ostla 
using a segmental approach Is performed lo electrically disconnect the arrhythmogenic 
foci within the PV’s from the left atrium. Early recurrence of atriaf fibrillation (ERAF) within 
24 hrs after the ablation is occasionally encountered. The clinical significance of ERAF 
has not been evaluated. 
Objective: To determine the prevalence and clinical significance of ERAF after isolation 
of PVs in patients with paroxysmal or persistent atrial fibrillation (AF). 
Methods: PV isolation was performed in 51 men and 11 women (mean age t SD = 52 i 
11 years) who had paroxysmal or persistent AF for 6.2 f 5.6 years. One patient had 
ischemic hearl disease and 3 had noniachemic cardiomyopathy. AF was paroxysmal in 
54 and persistent in 6 patients. All PVs with PV potentials were targeted using activation 
mapping guided with a decapolar Lasso catheter positioned within 5mm of the ostium. 
Complete electrical isolation was determined by elimination of all high-frequency PV 
potentials. ERAF was defined as any episode of atrial fibrillation that occurred within 24 
hours after the ablation procedure. 
Results: In 49 patients. the left superior and inferior and right superior PVs (LSPV, LIPV, 
and RSPV) and in 13 patients, all 4 PVs were targeted. 01 the 196 Pv’s, 163 (95%) were 
completely isolated. In 46 of 62 patients (77%). all targeted PVs were completely iso- 
lated. ERAF occurred in 7 of 62 patients (11%). Among the 7 patients with ERAF, there 
was no significant difference in the Incidence of ERAF between patients who had com- 
plete (n=4) and incomplete (n=3) isolation of all targeted PVs (p=NS). After 55i42 days 
of follow-up, 3 of the 7 patients who had ERAF were free of AF, 1 had significant improve- 
ment in the frequency of symptoms and 3 had no improvement. The incidence of recur- 
rence of AF was similar in patients with ERAF who had complete (2 of 4) and incomplete 
(2 of 3) isolation. 
Conclusions: ERAF within 24 hours may not be predictive of the clinical outcome during 
the first several weeks of follow-up. This implies that ERAF may be caused by a transient 
phenomenon such as an acute inflammatory response. 
9:00 a.m. 
885-3 Pulmonary Veins lsolatlon for Treatment of Atrial 
Fibrillation in Patients With Impaired Left Ventricular 
Function 
Mro Perez-w, Nassir F. Marrouche, Walid Saliba, Christopher Cole, Ahmad 
Abdul-Karim, Robert Schweikett, David 0. Martin, Eduardo Saad. Thomas Dresing, 
Andrea Natale, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Pulmonary veins (PVs) isolation for the treatment of atrial fibrillation (AF) 
has been well defined. The efficacy and safety of this approach in patients with impaired 
LV function (LVF) is lacking. In this study we describe the long-term success rates and 
follow-up of PVs isolation using the circular mapping technique in patients with impaired 
LVF. Methods and Results: Out of 182 patients (141 men; mean age 53+/-11 years) 
underwent focal mapping and ablation of AF 17 (9%) presented with impaired LVF (mean 
ejection fraction 38+/-7%, range 25-45%). Mean left atrial size and AF duration were 5+/- 
0.4 cm and 7+/-5 years, respectively. Ten patients had ischemic cardiomyopathy (CM), 3 
idiopathic CM, 3 valvular heart disease, and 1 hypertensive heart disease. All patients 
failed 4 +/- 0.9 antiarrhythmic drugs (AAD). 58 PVs were mapped and successfully 
ablated using circular mapping. After a mean follow-up of 5+/-2 months, 3 patients (17%) 
experienced recurrence of AF. Two are controlled on drugs and one underwent success- 
ful re-ablation. No PV stenosis (SO% narrowing) was seen in these patients. 
Conclusion: Isolation of the PV for the treatment of atrial fibrillation appeared effective 
and safe in patients with impaired LV function. In this preliminary experience, the 
response lo PV isolation of patients with LV dysfunction was similar to the rest of the pop 
ulation undergoing the procedure. 
9:15 a.m. 
885-4 Clinical Significance of Residual Pulmonary Vein 
Potentials After Pulmonary Vein Isolatlon in Patients 
With Paroxysmal Atria1 Fibrillation 
H&t&c& Hiroshi Tada, Mehmet Ozaydin, Sohail Hassan, Christoph Scharf, Aman 
Chugh, Radmira Greenstein, Frank Pelosi, Jr., Bradley P. Knight, S. Adam Strickberger, 
Fred Morady, University of Michigan, Ann Arbor, Minnesota. 
Background: After electrical isolation of pulmonary veins (PVs), low-amplitude, low-fre- 
quency PV potentials may persist despite vigorous attempts at ablation. The purpose of 
this study is to determine tha prevalence end clinical significance of these potentials. 
Methods: In 51 men and 11 women (mean age f SD = 52 f 11 years) with atrial fibrilla- 
tion (duration = 6.2 f 5.6 years; 14 f 12 episodes per month), PV isolation was guided by 
identification of PV potentials recorded with a circular mapping catheter. AIrial fibrillation 
was paroxysmal in 54 and persistent in 6 patients. All PVs with fascicular PV potentials 
were targeted. Radiofrequency (RF) energy was delivered at the earliest activation site 
within 5mm of the ostium at a maximum temperature of 52’C and a power of 35W for 45 
sets. Complete isolation was defined as the elimination of high frequency PV potentials 
and / or dissociation of the electrical activity within a PV from the lefi atrium. Residual 
potentials ware defined as low-amplitude (c0.5mV) and low-frequency potentials that fol- 
